Breast Cancer Therapeutics:
From Diagnosis to Enhancing Clinical Trial Protocols

INGENŪ CRO

Introduction

Breast cancer remains one of the most common and impactful malignancies affecting women worldwide.

Breast cancer is characterized by the uncontrolled growth of breast cells. It is not a single disease but a group of diseases, with various subtypes classified based on genetic, molecular, and histopathological criteria. These subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer, each differing significantly in prognosis, treatment response, and clinical outcomes.

Historically, breast cancer was treated with radical mastectomy, often without real hope for long-term survival. Over the decades, our understanding of the disease has advanced dramatically. The 20th century saw the development of mammography, improvements in surgical techniques, and the introduction of adjuvant therapies, which have all contributed to increased survival rates. More recently, the focus has shifted towards personalized medicine, driven by a deeper genetic and molecular understanding of the disease, allowing for targeted therapy approaches.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Key Characteristics and an Evolving Understanding

Breast cancer is characterized by the uncontrolled growth of breast cells. The disease typically presents as a lump or mass within breast tissue, though other symptoms such as nipple discharge, skin changes, or a change in breast size or shape can also be indicative. Breast cancer is not a single disease but a group of diseases, with various subtypes classified based on genetic, molecular, and histopathological criteria. These subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer, each differing significantly in prognosis, treatment response, and clinical outcomes.

Historical Perspectives and Evolution

Historically, breast cancer was treated with radical mastectomy, often without real hope for long-term survival. Over the decades, our understanding of the disease has advanced dramatically. The 20th century saw the development of mammography, improvements in surgical techniques, and the introduction of adjuvant therapies, which have all contributed to increased survival rates. More recently, the focus has shifted towards personalized medicine, driven by a deeper genetic and molecular understanding of the disease, allowing for targeted therapy approaches.

Contributing Factors

Biological Factors:

- Genetic mutations, such as those in the BRCA1 and BRCA2 genes, significantly increase the risk of developing breast cancer. Hormonal influences, particularly exposure to estrogen and progesterone, are also crucial in the disease's pathogenesis.

Psychological Factors:

- The psychological impact of breast cancer diagnosis and treatment can influence patient outcomes. Stress, coping mechanisms, and psychological support play roles in the treatment response and overall quality of life for patients.

Environmental Factors:

- Factors such as lifestyle, diet, and exposure to certain chemicals have been linked to breast cancer risk. Additionally, epidemiological studies suggest that environmental estrogens might contribute to higher incidence rates.

Diagnostic Evolution and Criteria

ICD-11 Codes for Breast Cancer

- **2C60 - Carcinoma of breast, specialized type:** Carcinomas that are classified under more specific or specialized categories.
- **2C61 - Invasive carcinoma of breast:** Refers to breast cancers that have invaded surrounding breast tissue.
- **2C62 - Inflammatory carcinoma of breast:** A rare and aggressive form that blocks lymph vessels in the skin of the breast.
- **2C63 - Malignant phyllodes tumor of breast:** Rare breast tumors that are mostly benign but can be malignant or borderline.
- **2C64 - Solid papillary carcinoma of breast with evidence of invasion:** A rare type of breast cancer typically seen in older women, characterized by papillae.
- **2C65 - Hereditary breast and ovarian cancer syndrome:** Most commonly associated with mutations in the BRCA1 & BRCA2 genes.
- **2C6Y - Other specified malignant neoplasms of breast:** This category is used when the breast cancer does not fit into the more common types but can still be specified based on its characteristics.
- **2C6Z - Malignant neoplasms of breast, unspecified:** This code is used when the breast cancer is confirmed but does not have enough information to be classified into a more specific category.

Evolution of Diagnostic Criteria

The evolution of diagnostic criteria for breast cancer has seen a shift from a predominantly clinical and morphological basis to include molecular and genetic markers. Historically, the classification focused mainly on observable patterns and the extent of disease (stage). Over the years, with advances in molecular biology and genetics, the criteria have expanded to include receptor status such as ER, PR, and HER2, which are critical for targeted therapies. These changes have enabled more personalized treatment approaches, significantly affecting survival rates and quality of life for patients.

Impact on Clinical & Research Perspectives

The changes in diagnostic criteria have had profound impacts on both clinical and research perspectives. Clinically, the integration of molecular markers into the ICD have allowed for more nuanced patient management strategies. These changes have not only improved therapeutic outcomes but have also helped in the stratification of patients into more homogenous groups for clinical trials, enhancing the robustness of research findings.

Epidemiological Landscape of Breast Cancer

Age-Related Incidence

Breast cancer is predominantly a disease of aging, with the highest incidence rates observed in women aged 55 years and older. However, it is not uncommon in younger women, where it tends to present as more aggressive forms. The age at diagnosis not only influences the biological behavior of the cancer but also affects treatment decisions and outcomes. Understanding age-related trends is crucial for developing age-specific screening and prevention strategies that can help in early detection and management of the disease.

Racial and Ethnic Disparities

The incidence and survival rates of breast cancer vary significantly among different racial and ethnic groups. For instance, while Caucasian women in the U.S. are more likely to be diagnosed with breast cancer, African American women are more likely to die from the disease. These disparities can be attributed to a combination of factors including genetic differences, lifestyle and environmental exposures, as well as variations in access to healthcare and socioeconomic status.

Geographical Variations

Geographic location is another critical factor in the epidemiology of breast cancer. Variations in incidence rates across different regions and countries can reflect differences in genetic factors, lifestyle, dietary habits, and the prevalence of screening programs. For instance, rates are generally higher in developed regions such as North America and Europe compared to developing countries. This could be linked to lifestyle factors associated with urbanization and western diets but also to the availability of better diagnostic facilities and screening programs.

Genetic Predispositions

Genetics play a fundamental role in the risk of developing breast cancer. Mutations in genes such as BRCA1 and BRCA2 significantly increase the risk and are associated with hereditary breast and ovarian cancer syndrome. However, these mutations account for a small percentage of cases overall. Other genetic factors and how they interact with environmental exposures are still being researched. Understanding these genetic markers and their implications for breast cancer risk is pivotal for genetic counseling and deciding on preventive strategies such as prophylactic surgeries or targeted therapies.

INGENŪ CRO

Pivotal Endpoints for Breast Cancer Clinical Trials

1. Overall Survival (OS):

OS refers to the duration of time from the start of treatment until death from any cause. It is considered the gold standard in oncology trials because it directly measures the treatment's impact on survival.

2. Progression-Free Survival (PFS):

The time during and after treatment that a patient lives with the disease without it getting worse. PFS is valuable for assessing the efficacy of a treatment in delaying the progression of the disease.

3. Disease-Free Survival (DFS):

Used primarily in adjuvant treatment trials, DFS refers to the length of time after primary treatment ends that the patient survives without any signs of breast cancer.

4. Objective Response Rate (ORR):

This measures the proportion of patients whose cancer shrinks or disappears after treatment. ORR includes complete responses and partial responses.

5. Quality of Life (QoL):

This is increasingly important in assessing the benefits of cancer treatments that may not significantly extend survival but improve symptom management and overall well-being.

6. Time to Progression (TTP):

Similar to PFS, TTP measures the time from the start of treatment until the cancer progresses. Unlike PFS, TTP does not include deaths, focusing only on disease progression.

7. Duration of Response:

The length of time that the disease remains in partial or complete response before progressing. DoR helps in understanding how long a treatment effect lasts after the initial response.

Challenges in Determining Endpoints in Breast Cancer Clinical Trials

1. Overall Survival (OS):

The definitive measure of a treatment's success, overall survival can require long follow-up periods, which can delay trial results and potentially slow down the approval of beneficial treatments. Additionally, treatments that improve quality of life but have a more modest impact on overall survival may be undervalued.

2. Progression-Free Survival (PFS):

While PFS is useful for evaluating the efficacy of a treatment in controlling disease progression, it may not always correlate with an overall survival benefit. This can lead to situations where a treatment appears effective in the short term but does not ultimately extend life expectancy, complicating the assessment of its true clinical benefit.

3. Disease-Free Survival (DFS):

Similar to PFS, the measurement of DFS can be affected by the sensitivity of the methods used to detect disease recurrence. Small variations in imaging technology or biopsy techniques can lead to inconsistencies in how recurrence is identified, affecting the reliability of DFS as an endpoint.

4. Objective Response Rate (ORR):

ORR requires precise and consistent measurement of tumor size and response, which can vary significantly depending on the imaging modalities used and the criteria for measuring response.

5. Quality of Life (QoL):

Quality of life is a subjective endpoint that relies on patient-reported outcomes. Variability in patient perception, response bias, and the influence of external factors can affect the accuracy and consistency of QoL measurements.

6. Time to Progression (TTP):

Like PFS, TTP does not account for overall survival and can be influenced by the timing and frequency of assessments. If assessments are not scheduled appropriately, or if there is a delay in recognizing progression, TTP data can be misleading.

7. Duration of Response (DoR):

Measuring the duration of response effectively requires continuous and often long-term monitoring of patients, which can be resource-intensive. The criteria for defining the end of a response must be clear and consistent to ensure that DoR is measured accurately across different studies and settings.

NGENŪ CRO

Five FDA-Approved Treatments for Breast Cancer

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Trastuzumab (Herceptin)	1998	Genentech	Monoclonal antibody targeting HER2 receptors	Reduces risk of cancer recurrence
Tamoxifen (Nolvadex/ Soltamox)	1977	AstraZeneca/ Savient Pharmaceuticals	Selective estrogen receptor modulator (SERM)	Prevents tumor growth by blocking estrogen
Anastrozole (Arimidex)	1995	AstraZeneca	Aromatase inhibitor	Lowers estrogen levels, slowing cancer growth
Palbociclib (Ibrance)	2015	Pfizer	CDK 4/6 inhibitor	Delays progression of advanced cancer
Pertuzumab (Perjeta)	2012	Genentech	Monoclonal antibody targeting HER2 receptors	Used in combination with trastuzumab for early-stage breast cancer

Approved Product Analysis: Herceptin

Adjuvant Breast Cancer

Women receiving adjuvant chemotherapy for HER2 overexpressing breast cancer.

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Women (22-80 years)	Studies 1&2 Combined	Disease-Free Survival (DFS)	HER2 Overexpression (IHC 3+), Gene Amplification (FISH), LVEF Monitoring	52 weeks of Herceptin Treatment	N=3752 (pooled data from selected arms)	Not specified, analyzed for DFS
Women (21-80 years)	Study 3	Disease-Free Survival (DFS)	HER2 Overexpression (IHC 3+), Gene Amplification (FISH), High-Risk Features Assessment, LVEF Monitoring	52 weeks of Herceptin Treatment	N=3386 (1693 in each treatment arm)	Not specified, analyzed for DFS
Women (22-74 years)	Study 4	Disease-Free Survival (DFS)	HER2 Gene Amplification (FISH+), High-Risk Features Assessment, LVEF Monitoring	52 weeks of Herceptin Treatment	N=3222 (randomized in three arms)	Not specified, analyzed for DFS

Metastatic Breast Cancer

Women with metastatic breast cancer whose tumors overexpress the HER2 protein.

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Women with previously untreated metastatic breast cancer	Study 5	Time to Disease Progression, Overall Response Rate (ORR), Median Survival	HER2 Overexpression (IHC 2+, 3+)	Evaluated at each cycle, up to 6 cycles	N=469	Paclitaxel for prior anthracycline recipients (175 mg/m^2 every 21 days); Anthracycline + Cyclophosphamide for others (Doxorubicin 60 mg/m^2 or Epirubicin 75 mg/m^2 + Cyclophosphamide 600 mg/m^2 every 21 days)	Longer median time to progression, higher ORR, longer median duration of response, and longer median survival in Herceptin and chemotherapy group
Women with previously treated metastatic breast cancer	Study 6	Overall Response Rate (ORR)	HER2 Overexpression (IHC 2+, 3+), Response Evaluation Committee Assessment	Not specified	N=222	Herceptin as a single agent, initial dose 4 mg/kg IV, followed by weekly doses of 2 mg/kg IV	ORR of 14% with a 2% complete response rate and a 12% partial response rate

Approved Product Analysis: Soltamox

Metastatic Breast Cancer

Premenopausal women with advanced breast cancer / Men with metastatic breast cancer.

Population	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Premenopausal women with advanced breast cancer	Objective Response Rate, Time to Treatment Failure, Survival	Not specified	Not specified	Not specified	Tamoxifen vs. Ovarian Ablation (oophorectomy or irradiation)	Similar outcomes between treatments
Men with metastatic breast cancer	Objective Response Rate	Not specified	Not specified	132 evaluable patients	Tamoxifen	50% objective response rate in treated patients

Adjuvant Treatment of Breast Cancer

Women with ER-positive or ER-unknown breast cancer / Women with ER-poor breast cancer.

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Women with early breast cancer, ER-positive or ER-unknown	EBCTCG Worldwide Overviews (1985, 1990, 1995, 1998, 2011)	Overall Survival (OS), Recurrence-Free Survival (RFS)	Not specified, likely clinical trial outcomes and survival analysis	10 years, 15 years	36,689 (1998), 21,457 (2011)	Adjuvant tamoxifen, 20-40 mg/day for 1 to 5+ years	**10-year outcomes:** - Node-positive: OS 61.4% vs. 50.5%, RFS 59.7% vs. 44.5% - Node-negative: OS 78.9% vs. 73.3%, RFS 79.2% vs. 64.3% - Mortality reduction: 12%, 17%, 26% for 1, 2, 5+ years - Recurrence reduction: 21%, 29%, 47% for 1, 2, 5+ years **5-year outcomes:** Continued benefit in reducing recurrence and death
Women with ER-poor breast cancer	EBCTCG Worldwide Overviews (1985, 1990, 1995, 1998, 2011)	Recurrence-Free Survival (RFS), Overall Survival (OS)	Not specified, likely clinical trial outcomes and survival analysis	10 years, 15 years	Part of 36,689	Adjuvant tamoxifen, varied durations	Less clear benefits: - Recurrence reduction: 10% overall, 9% excluding contralateral breast cancer (2p = 0.02) - Mortality reduction: 6% (not significant)

Approved Product Analysis: Soltamox (cont.)

Contralateral Breast Cancer

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Premenopausal and postmenopausal women	1995 EBCTCG Overview	Incidence of Contralateral Breast Cancer	Not specified	Up to 10 years	32,422 from 36,689	Adjuvant tamoxifen (1 year, 2 years, 5 years)	Reduction in contralateral breast cancer: 13% (1 year), 26% (2 years), 47% (5 years); from 7.6 per 1,000 to 3.9 per 1,000 (5 years)
Swedish Breast Cancer Cooperative Group participants	Randomized trial	Incidence of Second Primary Breast Tumors	Not specified	Duration of trial (2 to 5 years)	Not specified	Adjuvant tamoxifen 40 mg/day	40% reduction in second primary tumors ($p < 0.008$)
Participants in NSABP B-14 trial	Randomized trial	Incidence of Second Primary Breast Cancers	Not specified	10 years after randomization	Not specified	Tamoxifen 20 mg/day for 5 years vs. placebo	Significant reduction; annual rate: 5.0 per 1,000 (tamoxifen) vs. 8.0 per 1,000 (placebo) ($p < 0.01$)
Postmenopausal women in ATAC trial	Randomized trial comparing treatments	Efficacy of Adjuvant Treatment	Not specified	Median follow-up of 33 months	9,366	Anastrozole 1 mg daily, tamoxifen 20 mg daily, or combination	No additional benefit of combination over tamoxifen alone in all patients and hormone receptor-positive subgroup

Ductal Carcinoma in Situ

Women with DCIS.

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Women with DCIS	Double-blind, randomized trial (NSABP B-24)	Incidence of Invasive Breast Cancer in the ipsilateral or contralateral breast	Not specified	Median follow-up of 74 months	1,804 (902 tamoxifen, 902 placebo)	Tamoxifen 20 mg/day (10 mg tablets twice daily) or placebo for 5 years	43% reduction in the incidence of invasive breast cancer with tamoxifen (RR = 0.57, 95% CI: 0.39 to 0.84, $p = 0.004$)

Approved Product Analysis: Arimidex

Adjuvant Treatment of Breast Cancer in Postmenopausal Women

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Postmenopausal women with operable breast cancer	Multicenter, double-blind, randomized trial (ATAC)	Primary: Disease-Free Survival; Secondary: Distant Disease-Free Survival, Incidence of Contralateral Breast Cancer, Overall Survival	Not explicitly mentioned, likely based on clinical assessments and RECIST for cancer studies	Median follow-up of 33 months	9,366	1. Anastrozole (ARIMIDEX) 1 mg daily 2. Tamoxifen 20 mg daily 3. Combination of anastrozole and tamoxifen	No efficacy benefit was demonstrated with the combination treatment when compared with tamoxifen alone. Treatment with the combination arm was discontinued.

First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer	Two double-blind, controlled clinical studies (0030 North America, 0027 Europe)	Primary: Time to Tumor Progression, Objective Tumor Response Rate; Secondary: Safety	Not specified, likely clinical assessments and RECIST for tumor response	Not specified	1021 patients randomized	1. Anastrozole (ARIMIDEX) 1 mg daily 2. Tamoxifen 20 mg daily	**Trial 0030:** Anastrozole showed statistically significant improvement in time to tumor progression over tamoxifen (p=0.006); similar objective tumor response rates. **Trial 0027:** Similar objective tumor response rates and time to tumor progression for both treatments.

Second-Line Therapy in Postmenopausal Women with Advanced Breast Cancer who had Disease Progression following Tamoxifen Therapy

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Postmenopausal women with advanced breast cancer post-tamoxifen therapy	Two controlled clinical trials (0004 North America; 0005 Europe)	Primary: TTP, ORR; Secondary: Survival, Rate of progression, Rate of prolonged stable disease	Union Internationale Contre le Cancer (UICC) criteria	Not specified	Over 375 patients in each trial	1. Anastrozole 1 mg daily 2. Anastrozole 10 mg daily 3. Megestrol acetate 160 mg daily	No significant differences in objective response rates, time to progression, or survival between anastrozole 1 mg and megestrol acetate. No advantage of anastrozole 10 mg over 1 mg.

Approved Product Analysis: Perjeta

Metastatic Breast Cancer

Patients with HER2-positive metastatic breast cancer.

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
HER2-positive metastatic breast cancer patients	Multicenter, double-blind, placebo-controlled trial	Primary: Progression-Free Survival (PFS); Secondary: Overall Survival (OS), Investigator-assessed PFS, Objective Response Rate (ORR), Duration of Response	Independent Review Facility (IRF) using RECIST 1.1	Median PFS assessed until disease progression, death, or up to 18 weeks after the last tumor assessment	808 patients (1:1 randomization)	PERJETA + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel; PERJETA was given at 840 mg initially, then 420 mg every 3 weeks. Trastuzumab was given at 8 mg/kg initially, then 6 mg/kg every 3 weeks. Docetaxel was given at 75 mg/m² every 3 weeks for at least 6 cycles, with possible escalation to 100 mg/m².	Significant increase in median PFS by 6.1 months in the PERJETA-treated group (18.5 months vs. 12.4 months in the placebo group). Hazard Ratio (HR) = 0.62 (95% CI: 0.51, 0.75), p < 0.0001. Interim OS HR = 0.66 (95% CI: 0.52, 0.84), p=0.0008.

Neoadjuvant Treatment of Breast Cancer

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Operable, locally advanced, or inflammatory HER2-positive breast cancer	**Study 2:** Multicenter, randomized trial	Primary: Pathological Complete Response (pCR)	Pathological assessment; FDA definition of pCR (ypT0/is ypN0)	Prior to surgery and after completing neoadjuvant therapy	417	1. Trastuzumab + Docetaxel 2. PERJETA + Trastuzumab + Docetaxel 3. PERJETA + Trastuzumab 4. PERJETA + Docetaxel	Higher pCR rates in the PERJETA + Trastuzumab + Docetaxel group. Specific pCR rates not detailed in initial data provided.
HER2-positive locally advanced, operable, or inflammatory breast cancer	**Study 3**: Phase 2 neoadjuvant study assessing cardiac safety	Primary: Pathological Complete Response (pCR)	Pathological assessment; pCR defined as ypT0/is ypN0 (no invasive cancer in breast and lymph nodes)	Prior to surgery and after completing neoadjuvant therapy	225	1. PERJETA + Trastuzumab + FEC, then PERJETA + Trastuzumab + Docetaxel 2. FEC alone, then PERJETA + Trastuzumab + Docetaxel 3. PERJETA + TCH (Docetaxel, Carboplatin, Trastuzumab)	pCR rates: 56.2%, 54.7%, and 63.6% for the respective regimens. Lower pCR rates in hormone receptor-positive tumors compared to hormone receptor-negative tumors.

Approved Product Analysis: Ibrance

IBRANCE plus Letrozole

Postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous systemic treatment for their advanced disease.

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Postmenopausal women with ER-positive, HER2-negative advanced breast cancer	International, randomized, double-blind, multicenter study (PALOMA-2)	Primary: Progression-Free Survival (PFS); Secondary: Overall Survival (OS)	Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST)	Final analysis not specified; OS data immature at last PFS analysis	666 (randomized 2:1)	IBRANCE (125 mg daily for 21 days followed by 7 days off) + letrozole vs. placebo + letrozole	Significant improvement in PFS with IBRANCE + letrozole. Consistent results across subgroups.

IBRANCE plus Fulvestrant

Population	Study Description	Endpoint	Scales Used	Time Point	Sample Size	Treatment Regimen	Magnitude of Improvement
Women with HR-positive, HER2-negative advanced breast cancer, pre/postmenopausal	International, randomized, double-blind, multicenter study (PALOMA-3)	Primary: Progression-Free Survival (PFS)	Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST)	Final analysis not specified; OS data immature at last PFS analysis	521 (randomized 2:1)	IBRANCE (125 mg daily for 21 days on, 7 days off) + fulvestrant vs. placebo + fulvestrant; Pre/perimenopausal women also received goserelin	Significant improvement in PFS with IBRANCE + fulvestrant. Consistent results across subgroups.

Analysis of Failed Breast Cancer Drug Candidates Over the Last Decade

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure
Letrozole	NCT00375752	Findings suggest that clinical response rate is not observed with the addition of zoledronic acid to a neoadjuvant treatment regimen with letrozole in postmenopausal subjects with hormone responsive breast cancer
Bazedoxifene Acetate	NCT00418236	This trial was to evaluate mammographic breast density changes associated with bazedoxifene, raloxifene and placebo in postmenopausal women. Findings suggest that bazedoxifene treatment did not affect age related breast density changes in postmenopausal women with osteoporosis.
Iniparib	NCT00938652	Findings suggest that the addition of iniparib to gemcitabine/carboplatin do not meet the pre-specified endpoints of overall survival and progressive free survival in the subjects with metastatic triple-negative breast cancer.
Exemestane	NCT00066573	Findings suggest that exemestane is not superior in reducing the cancer recurrence in postmenopausal women with receptor positive primary breast cancer when compared to anastrozole.
Sunitinib Malate	NCT00435409	Findings suggest that capecitabine alone or in combination with sunitinib is not much effective in reducing the tumor growth in subjects with metastatic breast cancer.

INGENŪ CRO

Common Failure Points in Breast Cancer Clinical Trials

1. Heterogeneous Patient Populations:

Breast cancer's diverse subtypes require distinct treatments, making unstratified trial populations potentially skew results due to varied treatment responses.

2. Inadequate Biomarker Validation:

Biomarkers like hormone receptor and HER2 status are crucial for breast cancer treatment decisions. Trials failing to validate these or new biomarkers risk losing key therapeutic targeting opportunities.

3. Suboptimal Dosing Regimens:

Breast cancer treatments require precise dosing to balance efficacy with toxicity. Incorrect dosing can be detrimental due to the narrow therapeutic window of some drugs used in treatment.

4. Poor Endpoint Selection:

Selecting relevant clinical endpoints is crucial. For example, the importance of endpoints like pathological complete response (pCR) in neoadjuvant breast cancer trials is unique to oncology and requires careful consideration .

5. Dropouts and Loss to Follow-Up:

This can be a significant issue in long-term breast cancer trials, such as those assessing adjuvant therapies where the effects of the treatment often require years of observation to understand fully.

6. Inadequate Control Groups:

For breast cancer, where standard treatments are well-established for different stages and subtypes, having a control group that does not reflect the current standard of care can lead to irrelevant or unethical findings.

7. Failure in Patient Adherence:

Adherence to breast cancer treatment protocols, particularly in regimens involving prolonged courses of hormonal therapies, can uniquely affect trial outcomes due to the chronic nature of treatment.

8. Lack of Interim Analysis:

In breast cancer, where treatment effects such as tumor shrinkage or progression can be observed relatively early, missing interim analyses can mean prolonged patient exposure to ineffective or harmful therapies.

Safety Concerns and Standard of Care Treatment Options

Safety Concerns

- **Surgery and Anesthesia-Related Risks:** Complications can include infections, bleeding, and reactions to anesthesia. Long-term effects may involve lymphedema, especially after lymph node removal.
- **Chemotherapy-Induced Side Effects:** These include nausea, vomiting, hair loss, fatigue, and increased risk of infections due to lowered white blood cell counts. Long-term exposure can also lead to cardiac and cognitive issues.
- **Radiation Therapy Risks:** Short-term side effects often involve skin irritation and fatigue, while long-term risks include the potential development of secondary cancers and heart disease, particularly with radiation exposure to the chest area.
- **Hormonal Therapy Concerns:** Treatments aimed at blocking hormones that fuel certain types of breast cancer can lead to menopausal symptoms, osteoporosis, and joint pain.
- **Targeted Therapy Issues:** While generally less harsh than chemotherapy, targeted therapies can cause side effects such as skin rashes, diarrhea, and liver problems. Rarely, they can lead to severe lung issues or heart damage.

Standard of Care Treatments

- **Surgery:** This is often the first line of treatment, including procedures such as lumpectomy or mastectomy depending on the extent of the cancer.
- **Radiation Therapy:** Typically used following surgery to eliminate any remaining cancer cells in the breast, chest wall, or axilla (armpit area).
- **Chemotherapy:** Often administered before (neoadjuvant) or after (adjuvant) surgery to reduce the risk of cancer recurrence, particularly for aggressive or advanced cancers.
- **Hormonal (Endocrine) Therapy:** For hormone receptor-positive cancers, therapies like tamoxifen or aromatase inhibitors are used to block the effects of estrogen or lower estrogen levels in the body.
- **Targeted Therapy:** Drugs like trastuzumab (Herceptin) are used for HER2-positive breast cancers to specifically target and kill cancer cells that overexpress the HER2 protein.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Breast Cancer

Improving clinical trial protocols for breast cancer is pivotal to advancing our understanding and treatment of the disease. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Stay Updated on Guidelines:

Regular updates and training on FDA guidelines can help ensure that trials are designed in compliance with the latest regulatory expectations, which can evolve, particularly in high-profile areas like breast cancer treatment.

2. Engage with FDA Early:

Early and ongoing engagement with the FDA can provide valuable feedback on trial design, helping to align it with regulatory standards and address any potential issues early in the development process.

3. Patient Stratification:

Utilize biomarkers and genetic profiling to stratify patient groups. This ensures that the trial targets the population most likely to benefit from the treatment, enhancing the statistical significance of the results.

4. Incorporate Novel Endpoints:

Develop and validate novel endpoints that can provide early indications of efficacy or more accurately reflect meaningful clinical outcomes, such as quality of life or long-term survival.

5. Broaden Inclusion Criteria:

Consider broadening inclusion criteria to enhance the diversity and representativeness of the trial population, ensuring that the findings are applicable to a wider patient base. Additionally, this could improve participant recruitment.

6. Enhance Patient Engagement:

Strategies to improve patient engagement and retention, such as patient education programs about the benefits and risks of participation, streamlined scheduling, and clinic visit transportation.

7. Statistical Analysis Plans:

Create detailed statistical analysis plans before trials, with provisions for handling missing data, multiplicity issues, and subgroup analyses, ensuring that the data analysis is robust and credible.

8. Robust Safety Monitoring:

Establish an independent data monitoring committee to regularly assess trial safety data, enabling informed decisions about continuing, modifying, or stopping the trial based on safety concerns.

Notable Key Opinion Leaders in Breast Cancer Research

Name	Specialty	Designation	Location	Brief Bio
Sarah-Jane Dawson (Ph.D., M.B.B.S)	Medical Oncology	Professor, Peter MacCallum Cancer Centre	Victoria, Australia	Professor Sarah-Jane Dawson is a consultant medical oncologist and the head of the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre in Melbourne. Professor Dawson's research has pioneered the development of circulating tumor DNA (ctDNA) as a non-invasive "liquid biopsy" for cancer diagnostics and management. Her work focuses on early detection, risk stratification, and disease monitoring in cancer through molecular biomarkers. This research has significant implications for improving patient outcomes by enabling personalized disease monitoring and informing therapeutic decisions.
Sudarsha Selva-Nayagam (MBBS , FRACP)	Medical Oncology; Hematology; Internal Medicine	Director, Royal Adelaide Hospital SA	South Australia	Dr. Sudarsha Selva-Nayagam is the Director of Medical Oncology at the Royal Adelaide Hospital. Dr. Selva-Nayagam has significantly contributed to the field of oncology by developing cancer services in the Northern Territory, including the innovative use of tele-oncology. His areas of interest include breast cancer, gynecological cancers, lung cancer, sarcoma, and lymphoma. He has also been involved in multidisciplinary cancer care teams at the Royal Adelaide Hospital, coordinating comprehensive care for cancer patients.
Claire Phillips (MD, TROG)	Radiation Oncology	Radiation Oncologist, Peter MacCallum Cancer Centre	Victoria, Australia	Dr. Claire Phillips is the lead radiation oncologist for the Brain and Spine Service at the Peter MacCallum Cancer Centre. She is also a longstanding member of the Breast Service at Peter Mac. Dr. Phillips's research interests include stereotactic photon radiotherapy for choroidal melanoma, synchrotron microbeam radiotherapy (MRT), and the treatment of oligometastatic brain disease. Her work aims to improve the precision and effectiveness of radiation therapy, thereby enhancing patient outcomes.
Sheau W Lok (MBBS, BMedSc, FRACP)	Medical Oncology	Breast Oncologist, The Royal Melbourne Hospital	Victoria, Australia	Dr. Sheau Wen Lok is a breast oncologist at the Peter MacCallum Cancer Centre. She also serves as a Cancer Genetics specialist at the Parkville and Austin Familial Cancer Centers. Dr. Lok's research interests include harnessing real-world evidence through multi-center breast cancer registries to inform clinical practice. She is the Australian co-chair of the BRCA-P study, an international breast cancer prevention trial for women with a BRCA1 gene mutation. Her work significantly impacts the development of new breast cancer therapies and the improvement of clinical practices.
Anand Murugasu (MBBS, FRACP)	Radiology	Consultant Histopathologist, The Royal Melbourne Hospital	Victoria, Australia	Dr. Anand Murugasu is a clinical pathologist at the Royal Melbourne Hospital, specializing in anatomical pathology. Dr. Murugasu has contributed to advancing the field of pathology through his research and clinical practice. His work is vital in ensuring accurate diagnoses, which directly impacts patient treatment plans and outcomes. He has been involved in research projects like the ANZ 1002 trial, which focuses on breast cancer treatment protocols.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com